578 related articles for article (PubMed ID: 23640384)
41. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
42. Endophthalmitis After Intravitreal Injections: Incidence, Presentation, Management, and Visual Outcome.
Dossarps D; Bron AM; Koehrer P; Aho-Glélé LS; Creuzot-Garcher C;
Am J Ophthalmol; 2015 Jul; 160(1):17-25.e1. PubMed ID: 25892127
[TBL] [Abstract][Full Text] [Related]
43. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection.
Roth DB; Chieh J; Spirn MJ; Green SN; Yarian DL; Chaudhry NA
Arch Ophthalmol; 2003 Sep; 121(9):1279-82. PubMed ID: 12963610
[TBL] [Abstract][Full Text] [Related]
44. Intravitreal bevacizumab vs sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia.
Wakabayashi T; Ikuno Y; Gomi F; Hamasaki T; Tano Y
Am J Ophthalmol; 2009 Oct; 148(4):591-596.e1. PubMed ID: 19589497
[TBL] [Abstract][Full Text] [Related]
45. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema.
Sohn HJ; Han DH; Kim IT; Oh IK; Kim KH; Lee DY; Nam DH
Am J Ophthalmol; 2011 Oct; 152(4):686-94. PubMed ID: 21782151
[TBL] [Abstract][Full Text] [Related]
46. [Role of intravitreal bevacizumab for resistant macular edema due to central retinal vein occlusion after failure of intravitreal triamcinolone acetonide].
Le Moigne O; Duncombe A; Portmann A; Muraine M; Genevois O
J Fr Ophtalmol; 2012 Nov; 35(9):700-4. PubMed ID: 22925843
[TBL] [Abstract][Full Text] [Related]
47. Outcome of intravitreal triamcinolone in uveitis.
Kok H; Lau C; Maycock N; McCluskey P; Lightman S
Ophthalmology; 2005 Nov; 112(11):1916.e1-7. PubMed ID: 16171868
[TBL] [Abstract][Full Text] [Related]
48. Anatomic and visual outcomes of noninfectious endophthalmitis after intravitreal triamcinolone.
Yoon SJ; Rhee DY; Marx JL; Blaha GR; Rogers AH; Baumal CR; Reichel E; Duker JS
Am J Ophthalmol; 2009 Jun; 147(6):1031-6. PubMed ID: 19268893
[TBL] [Abstract][Full Text] [Related]
49. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion.
Tao Y; Hou J; Jiang YR; Li XX; Jonas JB
Eye (Lond); 2010 May; 24(5):810-5. PubMed ID: 19696805
[TBL] [Abstract][Full Text] [Related]
50. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch.
Yamashiro K; Tsujikawa A; Miyamoto K; Oh H; Otani A; Tamuara H; Ooto S; Sasahara M; Iwama D; Yoshimura N
Retina; 2010 Mar; 30(3):485-90. PubMed ID: 19952993
[TBL] [Abstract][Full Text] [Related]
51. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial.
Sutter FK; Simpson JM; Gillies MC
Ophthalmology; 2004 Nov; 111(11):2044-9. PubMed ID: 15522370
[TBL] [Abstract][Full Text] [Related]
52. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide.
Jonas JB; Kreissig I; Spandau UH; Harder B
Am J Ophthalmol; 2006 Mar; 141(3):579-80. PubMed ID: 16490517
[TBL] [Abstract][Full Text] [Related]
53. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.
Cekiç O; Cakır M; Yazıcı AT; Alagöz N; Bozkurt E; Faruk Yılmaz O
Curr Eye Res; 2010 Oct; 35(10):925-9. PubMed ID: 20858114
[TBL] [Abstract][Full Text] [Related]
54. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.
Jonas JB
Acta Ophthalmol Scand; 2005 Dec; 83(6):645-63. PubMed ID: 16396641
[TBL] [Abstract][Full Text] [Related]
55. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
56. Endophthalmitis after intravitreal injection: the importance of viridans streptococci.
Chen E; Lin MY; Cox J; Brown DM
Retina; 2011 Sep; 31(8):1525-33. PubMed ID: 21878800
[TBL] [Abstract][Full Text] [Related]
57. Micropulsed laser photocoagulation and intravitreal triamcinolone acetonide injection for the treatment of retinal angiomatous proliferation.
Roth DB; Scott IU; Gloth JM; Green SN; Yarian DL; Wheatley M
Retina; 2007; 27(9):1201-4. PubMed ID: 18046225
[TBL] [Abstract][Full Text] [Related]
58. [Combined pharmacosurgery as treatment for diabetic macular edema: core pars plana vitrectomy and intravitreal injection of bevacizumab and triamcinolone].
Naser H; Koss MJ; Singh P; Koch F
Klin Monbl Augenheilkd; 2011 Oct; 228(10):910-4. PubMed ID: 21997827
[TBL] [Abstract][Full Text] [Related]
59. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?
Schaal S; Kaplan HJ; Tezel TH
Ophthalmology; 2008 Dec; 115(12):2199-205. PubMed ID: 18930553
[TBL] [Abstract][Full Text] [Related]
60. Short-term complications of intravitreal injections of triamcinolone and bevacizumab.
Jonas JB; Spandau UH; Schlichtenbrede F
Eye (Lond); 2008 Apr; 22(4):590-1. PubMed ID: 18292795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
